Business
Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights
Expect to report topline results from INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, in the third quarter of
About this update from Acumen Pharmaceuticals, Inc.
[{"type":"text","content":"Expect to report topline results from INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, in the third quarter of 2023Cash, cash equivalents and marketable securities of $183.8 million as of March 31, 2023 expected to be sufficient to support clinical and operational activities through 2025Company to host conference call and webcast today at 8:00 a.m. ET CHARLOTTESVILLE, Va. and Carmel, Ind., May 09, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the first quarter of 2023 and provided a business update. “In the first quarter, we remained focused on executing the Phase I INTERCEPT-AD trial of ACU193, our novel therapeutic for the treatment of early Alzheimer’s disease. We are pleased to confirm our expectation that we will share the first clinical data in the field from a monoclonal antibody with high selectivity for toxic amyloid beta oligomers in the upcoming third quarter,” said Daniel O’Connell, President and Chief Executive Officer of Acumen. “Amid a dynamic and evolving Alzheimer’s landscape, we look forward to reporting clinical evidence of the overall safety profile, pharmacokinetic data, including the potential for monthly dosing, as well as target engagement. We expect that these topline data will serve as the basis for an anticipated interaction with the FDA in the fourth quarter to inform our next phase of development for ACU193.” Recent Business Highlights and Anticipated Milestones In February 2023, enrollment was completed in our Phase 1 INTERCEPT-AD trial, investigating the safety, tolerability, pharmacokinetics and target engagement of ACU193 in patients with early AD. Acumen continues to anticipate reporting topline results from this trial in the third quarter of 2023. In March 2023, the Company presented research at the International Conference on Alzheimer’s and Parkinson’s Diseases (ADPD). The research demonstrated the utility of a human in vitro model of induced pluripotent stem cell (iPSC)-derived excitatory neurons for a better understanding of which forms of amyloid beta oligomers contribute to the pathogenesis of AD in the human b...